Dead space and inhaled nitric oxide in pediatric ARDS
Official title: Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome
Funded at Children's Hospital of Los Angeles · NIH-11411416 · Data updated 2026-11-12
This project looks at whether measuring dead space and using inhaled nitric oxide can help improve outcomes for children with acute respiratory distress syndrome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hospital of Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 20, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $712,035 |
| NIH project number | 5R01HL173488-03 |
| Project ID | NIH-11411416 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children and adolescents with ARDS, especially those who fit pediatric criteria and are treated at participating centers.
✕Less likely to help
Some patients may not experience measurable benefit if AVDSf does not prove to predict outcomes or if treatments like inhaled nitric oxide are not effective for specific cases.
What this research studies
Pediatric ARDS has a high mortality rate, and current therapies haven’t reliably reduced death. The study focuses on identifying real-time, easily measured markers of lung dysfunction, specifically the end tidal alveolar dead space fraction (AVDSf), to understand why treatments work for some kids but not others. By using routine monitoring data, the researchers aim to see if AVDSf correlates more strongly with mortality risk than traditional severity measures. If AVDSf proves informative, it could guide more targeted therapies, including the potential use of inhaled nitric oxide in appropriate cases. The work is led by a team at Children’s Hospital of Los Angeles and seeks to translate findings into practice to tailor treatment for pediatric ARDS patients.
Why it matters
Potential benefit: If successful, this research could enable real-time stratification of pediatric ARDS patients to personalize therapy and potentially reduce mortality.
How similar studies have gone: Preliminary single-center findings suggest AVDSf relates to mortality risk better than some traditional markers, but broader validation is needed.
Where this research is happening
-
Children's Hospital of Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Bhalla, Anoopindar — Children's Hospital of Los Angeles
- Study coordinator: Bhalla, Anoopindar
Related research
Other NIH-funded projects on the same topics.
-
Identifying ARDS patients who may benefit from paralytics guided by high-frequency clinical data
This grant aims to help doctors figure out which adults with ARDS are most likely to benefit from paralytic medications using detailed bedside data and electronic health records.
-
Resilience endotypes and early ARDS detection using biomarkers and AI
A Duke University team is using biomarkers and smart data analysis to detect ARDS early and uncover patterns that predict how patients recover.
-
PAR1’s role in lung lymphatics and a new therapy approach for ARDS
This grant explores how the thrombin receptor PAR1 affects lung lymphatics to understand and ultimately reduce lung injury in ARDS patients.
-
Immune, hormone, and muscle energy links to recovery after ARDS
This project looks at why some ARDS survivors have ongoing weakness and how immune, hormone, and muscle energy factors might influence recovery.</n>
-
Understanding why some people with severe lung injury get worse and how to tailor therapy
A patient-focused program that looks at why people develop sepsis-associated ARDS and how their bodies respond, with the goal of guiding better, personalized treatments.
-
Imaging the Pulmonary Circulation to Personalize ARDS Care
A patient-focused look at using advanced imaging to understand lung blood flow in ARDS so doctors can tailor treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.